TFPI polyclonal, anti-human, mouse, rat

Background:
Inhibition of Factor VIIa tissue factor activity requires a plasma component (tissue factor pathway inhibitor (TFPI), lipoprotein-associated coagulation inhibitor (LACI) or extrinsic pathway inhibitor (EPI)) and factor Xa. TFPI directly inhibits factor Xa, and, in an Xa-dependent fashion, also inhibits the Factor VIIa tissue factor catalytic complex. TFPI is a multivalent, Kunitz-type proteinase inhibitor that circulates in association with plasma lipoproteins VLDL, LDL, and HDL. TFPI-2 (also known as placental protein 5) is a related glycoprotein that was originally isolated from human placenta.

Alternative Name:
convertin, EPI, Extrinsic pathway inhibitor, LACI, Lipoprotein associated coagulation inhibitor, Lipoprotein-associated coagulation inhibitor, TFI, TFPI 1, TFPI, TFPI1, TFPI1, Tissue factor pathway inhibitor,

Application Dilution: WB: 1:500~1:2000

Specificity: TFPI polyclonal antibody detects endogenous levels of TFPI protein.

Immunogen:
Recombinant full length Human TFPI.

MW: ~ 35, 43 kDa

Swis Prot.: P10646

Purification & Purity:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).

Format:
1mg/ml in PBS with 0.1% Sodium Azide, 50% Glycerol.

Storage:
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

For research use only, not for use in diagnostic procedure.